Latest From Pharmos Corp.
German firm, vasopharm, said it is seeking a strategic partner to accelerate the further development of VAS203 for traumatic brain injury (TBI), after reporting that Phase IIa results for the drug candidate had 'exceeded expectations'.
The Iselin, New Jersey firm Pharmos is touting positive data from a proof-of-concept trial of its last remaining pipeline product in the hope of cashing in on the gout goldrush before its own purse is empty. The company has developed levotofisopam, an S-enantiomer of the benzodiazepine tofisopam, for the treatment of gout, and is hoping that a partner will step forward for the drug.
Salix Pharmaceuticals' broad spectrum antibiotic Xifaxan (rifaximin) met its primary endpoint in two Phase III trials, providing symptomatic relief from non-constipation irritable bowel syndrome (IBS). The company's share price soared by 51% to close at $20.22 on September 14th on Nasdaq following the news.
A court in Brno, in the south-east of the Czech Republic, has upheld a ruling of the country's office for the protection of competition (UOHS) regarding the country's four largest pharmaceutical distributors interrupting drug supplies to hospitals almost three years ago.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pharmos Corp.
- Senior Management
- Colin Neill, Pres., CFO, Sec'y & Treasurer
- Contact Info
Phone: (732) 452-9556
99 Wood Ave. S
Iselin, NJ 08830
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.